Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival

Sullivan, R. D., Mehta, R. M., Tripathi, R., Gladysheva, I. P., & Reed, G. L.

International journal of molecular sciences 20.16 (2019): 3886.

Heart failure (HF) patients frequently have elevated plasma renin activity. We examined the significance of elevated plasma renin activity in a translationally-relevant model of dilated cardiomyopathy (DCM), which replicates the progressive stages (A-D) of human HF. Female mice with DCM and elevated plasma renin activity concentrations were treated with a direct renin inhibitor (aliskiren) in a randomized, blinded fashion beginning at Stage B HF. By comparison to controls, aliskiren treatment normalized pathologically elevated plasma renin activity (p < 0.001) and neprilysin levels (p < 0.001), but did not significantly alter pathological changes in plasma aldosterone, angiotensin II, atrial natriuretic peptide, or corin levels. Aliskiren improved cardiac systolic function (ejection fraction, p < 0.05; cardiac output, p < 0.01) and significantly reduced the longitudinal development of edema (extracellular water, p < 0.0001), retarding the transition from Stage B to Stage C HF. The normalization of elevated plasma renin activity reduced the loss of body fat and lean mass (cachexia/sarcopenia), p < 0.001) and prolonged survival (p < 0.05). In summary, the normalization of plasma renin activity retards the progression of experimental HF by improving cardiac systolic function, reducing the development of systemic edema, cachexia/sarcopenia, and mortality. These data suggest that targeting pathologically elevated plasma renin activity may be beneficial in appropriately selected HF patients.

Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy Effects on Edema, Cachexia, and Survival

Products Used in this Publication

Catalog NumberCASProduct NamePrice
B0293-466286173334-58-2Aliskiren HemifumarateInquiry

Related Products

Catalog NumberCASProduct NamePrice
173334-57-1173334-57-1AliskirenInquiry
173338-07-3173338-07-3N-Boc AliskirenInquiry
900811-48-5900811-48-5Amino Lactone ImpurityInquiry
173400-13-0173400-13-0Aliskiren Acid ImpurityInquiry
1630036-82-61630036-82-6Aliskiren Hemifumarate (SSSRisomer) ImpurityInquiry